P-101: Advantages of Recombinant Follicle- Stimulating Hormone over Human Menopausal Gonadotropin for Ovarian Stimulation in Intrauterine Insemination: A Randomized Clinical Trial in Unexplained Infertility

Authors

  • A Aaleyasin Department of Obstetrics and Gynecology, School of Medicine, Tehran University of Medical Sciences, Tehran, Irananes.9
  • A Kokab Department of Obstetrics and Gynecology, School of Medicine, Tehran University of Medical Sciences, Tehran, Irananes.9
  • M Aghahosseini Department of Obstetrics and Gynecology, School of Medicine, Tehran University of Medical Sciences, Tehran, Irananes.9
  • M Rashidi Department of Obstetrics and Gynecology, Shahid Akbari Hospital, Iran University of Medical Sciences, Tehran, Iranes.9
  • S Loloi Departman of Obstetrics and Gynecology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Z Najmi Department of Obstetrics and Gynecology, Hazrate Rasool Akram Hospital, Iran University of Medical Sciences, Tehran, Iranher".
Abstract:

Background To compare two different gonadotropin preparations, human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (rFSH), combined with clomiphene citrate (CC) in women with unexplained infertility undergoing intrauterine insemination (IUI). MaterialsAndMethods In this prospective clinical trial, couples prepared for IUI cycles were randomly allocated to two groups either to receive CC and hMG (group A, n=127) or CC and rFSH (group B, n=132) for ovarian stimulation. Outcomes including rates of clinical pregnancy, miscarriage, OHSS, multiple pregnancy, cancellation, and live birth were compared between groups Results Duration of gonadotropin therapy was significantly shorter in group B (5.1 ± 0.84 vs. 4.7 ± 0.8 days, CI=95%, P

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

comparison of recombinant human follicle stimulating hormone (rhfsh), human chorionic gonadotropin (hcg) and human menopausal gonadotropin (hmg) on semen parameters after varicocelectomy: a randomized clinical trial

background: the most frequent physical finding in infertile men is varicocele, in which one of the mechanisms that can affect seminal parameters is oxidative stress. objective: our study aimed, for the first time, to compare the efficacy of recombinant human follicle-stimulating hormone (rhfsh), human chorionic gonadotropin (hcg) and human menopausal gonadotropin (hmg) on sperm parameters and f...

full text

Comparison of daily and alternate day recombinant follicle-stimulating hormone stimulation protocols for intrauterine insemination.

OBJECTIVE To determine the efficacy of daily versus alternate-day stimulation for patients undergoing intrauterine insemination (IUI). DESIGN Retrospective comparative study. SETTING University tertiary care center for infertility. PATIENT(S) Women with anovulatory or unexplained infertility for over 12 months who had not responded to or not conceived with clomiphene citrate treatment. ...

full text

Comparison of recombinant human follicle stimulating hormone (rhFSH), human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) on semen parameters after varicocelectomy: a randomized clinical trial

BACKGROUND The most frequent physical finding in infertile men is varicocele, in which one of the mechanisms that can affect seminal parameters is oxidative stress. OBJECTIVE Our study aimed, for the first time, to compare the efficacy of recombinant human follicle-stimulating hormone (rhFSH), human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) on sperm parameters and f...

full text

Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial.

To examine the role of recombinant human follicle stimulating hormone (rhFSH) in male idiopathic infertility a randomized, double-blind, placebo-controlled study was performed. Of 211 patients screened, 67 were finally included. After two pre-examinations, patients were randomized and treated for 12 weeks, either with 150 IU rhFSH or with placebo. Examinations (physical examination, scrotal ult...

full text

Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin

BACKGROUND Luteinizing hormone (LH) activity in human menopausal gonadotropin (hMG) preparations is derived from human chorionic gonadotropin (hCG) rather than LH. Therefore, we aimed to determine whether there are similarities in the endocrine and follicular profiles of serum and follicular fluid from controlled ovarian stimulation with the recombinant gonadotropins follicle-stimulating hormon...

full text

Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation.

BACKGROUND Gonadotropins are protein hormones which are central to the complex endocrine system that regulates normal growth, sexual development, and reproductive function. There is still a lively debate on which type of gonadotropin medication should be used, either human menopausal gonadotropin or recombinant follicle-stimulating hormone. The objective of the study was to perform a systematic...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 9  issue 2

pages  85- 85

publication date 2015-09-01

{@ msg @}

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023